Toward more durable COVID vaccines – Elarex Inc.

ORIGINAL POST,, December 10, 2021

McMaster spinout company earns key international grant

Newswise — HAMILTON, ON, Canada – A new company spawned by McMaster University innovation in the arena of vaccine manufacturing has received a grant from the Bill & Melinda Gates Foundation.

Elarex Inc., based in Burlington, ON, has been awarded a $1.2M Cdn grant from the non-profit humanitarian foundation to develop a new technology for keeping liquid mRNA vaccines safe and viable without the deep-freeze that is necessary today for storing and transporting such vaccines.

Maintaining the “cold chain” from the point of manufacture through the administration of single doses is necessary, but it presents a cumbersome, resource-intense, and expensive barrier to the equitable global distribution of vaccines, particularly in developing countries. A technology breakthrough in improving the thermostability of mRNA liquid nanoparticles in liquid form would enable better use and distribution of mRNA vaccines in low- and middle-income countries.

Elarex was created in 2019 to commercialize technology developed by a team including McMaster’s Chair of Chemical Engineering Carlos Filipe, an Elarex co-founder and scientific advisor.

To continue reading CLICK HERE

Share this article
View All Categories

Featured iF Clients